209 related articles for article (PubMed ID: 16600392)
1. Increasing prevalence of HIV-1 protease inhibitor-associated mutations correlates with long-term non-suppressive protease inhibitor treatment.
Kagan RM; Cheung PK; Huard TK; Lewinski MA
Antiviral Res; 2006 Aug; 71(1):42-52. PubMed ID: 16600392
[TBL] [Abstract][Full Text] [Related]
2. Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.
Gonzalez LM; Santos AF; Abecasis AB; Van Laethem K; Soares EA; Deforche K; Tanuri A; Camacho R; Vandamme AM; Soares MA
J Antimicrob Chemother; 2008 Jun; 61(6):1201-4. PubMed ID: 18356151
[TBL] [Abstract][Full Text] [Related]
3. Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients for whom their first protease-inhibitor antiretroviral regimens failed.
Perno CF; Cozzi-Lepri A; Forbici F; Bertoli A; Violin M; Stella Mura M; Cadeo G; Orani A; Chirianni A; De Stefano C; Balotta C; d'Arminio Monforte A;
J Infect Dis; 2004 Jun; 189(11):1983-7. PubMed ID: 15143463
[TBL] [Abstract][Full Text] [Related]
4. Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation.
van Maarseveen NM; Wensing AM; de Jong D; Taconis M; Borleffs JC; Boucher CA; Nijhuis M
J Infect Dis; 2007 Feb; 195(3):399-409. PubMed ID: 17205479
[TBL] [Abstract][Full Text] [Related]
5. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.
Kozal MJ; Hullsiek KH; Leduc R; Novak RM; MacArthur RD; Lawrence J; Baxter JD;
Antivir Ther; 2006; 11(4):457-63. PubMed ID: 16856619
[TBL] [Abstract][Full Text] [Related]
7. Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.
Svedhem V; Lindkvist A; Bergroth T; Knut L; Sönnerborg A
J Med Virol; 2005 Aug; 76(4):447-51. PubMed ID: 15977242
[TBL] [Abstract][Full Text] [Related]
8. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V
Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
[TBL] [Abstract][Full Text] [Related]
9. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.
Holguín A; Paxinos E; Hertogs K; Womac C; Soriano V
J Clin Virol; 2004 Nov; 31(3):215-20. PubMed ID: 15465415
[TBL] [Abstract][Full Text] [Related]
10. Resistance to protease inhibitors.
Kuritzkes DR
J HIV Ther; 2002 Nov; 7(4):87-91. PubMed ID: 12733606
[TBL] [Abstract][Full Text] [Related]
11. The HIV-1 protease substitution K55R: a protease-inhibitor-associated substitution involved in restoring viral replication.
Margerison ES; Maguire M; Pillay D; Cane P; Elston RC
J Antimicrob Chemother; 2008 Apr; 61(4):786-91. PubMed ID: 18252693
[TBL] [Abstract][Full Text] [Related]
12. Persistence of mutations during replication of an HIV library containing combinations of selected protease mutations.
Song W; Maeda Y; Tenpaku A; Harada S; Yusa K
Antiviral Res; 2004 Mar; 61(3):173-80. PubMed ID: 15168798
[TBL] [Abstract][Full Text] [Related]
13. Low prevalence of antiretroviral resistance among persons recently infected with human immunodeficiency virus in two US cities.
Sullivan PS; Buskin SE; Turner JH; Cheingsong R; Saekhou A; Kalish ML; Jones JL; Respess R; Kovacs A; Heneine W
Int J STD AIDS; 2002 Aug; 13(8):554-8. PubMed ID: 12194739
[TBL] [Abstract][Full Text] [Related]
14. Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy.
Balduin M; Sierra S; Däumer MP; Rockstroh JK; Oette M; Fätkenheuer G; Kupfer B; Beerenwinkel N; Hoffmann D; Selbig J; Pfister HJ; Kaiser R
J Clin Virol; 2005 Dec; 34(4):277-87. PubMed ID: 16191482
[TBL] [Abstract][Full Text] [Related]
15. Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients.
Vergne L; Stuyver L; Van Houtte M; Butel C; Delaporte E; Peeters M
J Clin Virol; 2006 May; 36(1):43-9. PubMed ID: 16563858
[TBL] [Abstract][Full Text] [Related]
16. Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients.
Torti C; Quiros-Roldan E; Monno L; Patroni A; Saracino A; Angarano G; Tinelli C; Lo Caputo S; Tirelli V; Mazzotta F; Carosi G; ;
J Med Virol; 2004 Sep; 74(1):29-33. PubMed ID: 15258965
[TBL] [Abstract][Full Text] [Related]
17. Comparison of protease genotype and phenotype in HIV-1 infected patients exposed to more than one protease inhibitor.
Gianotti N; Tambussi G; Boeri E; Lazzarin A
J Biol Regul Homeost Agents; 2001; 15(2):166-9. PubMed ID: 11501975
[TBL] [Abstract][Full Text] [Related]
18. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens.
Colonno R; Rose R; McLaren C; Thiry A; Parkin N; Friborg J
J Infect Dis; 2004 May; 189(10):1802-10. PubMed ID: 15122516
[TBL] [Abstract][Full Text] [Related]
19. Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali.
Derache A; Traore O; Koita V; Sylla A; Tubiana R; Simon A; Canestri A; Carcelain G; Katlama C; Calvez V; Cisse M; Marcelin AG
Antivir Ther; 2007; 12(1):123-9. PubMed ID: 17503757
[TBL] [Abstract][Full Text] [Related]
20. Effect of human immunodeficiency virus type 1 protease inhibitor therapy and subtype on development of resistance in subtypes B and G.
Palma AC; Abecasis AB; Vercauteren J; Carvalho AP; Cabanas J; Vandamme AM; Camacho RJ
Infect Genet Evol; 2010 Apr; 10(3):373-9. PubMed ID: 19577015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
